Biological
Tumor Infiltrating Lymphocyte
Tumor Infiltrating Lymphocyte is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_1
1
33%
Ph early_phase_1
2
67%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 1Safety & dosage
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Recruiting2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Early Phase 12 (66.7%)
Phase 11 (33.3%)
Trials by Status
recruiting267%
unknown133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingearly_phase_1
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
NCT05098197
recruitingearly_phase_1
A Study of GC101 TIL in Advanced Melanoma (10hospital)
NCT05098184
unknownphase_1
A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
NCT04538313
Clinical Trials (3)
Showing 3 of 3 trials
NCT05098197Early Phase 1
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
NCT05098184Early Phase 1
A Study of GC101 TIL in Advanced Melanoma (10hospital)
NCT04538313Phase 1
A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3